Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: cbio), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial updates, milestone payments, and cash runway projections for Catalyst Biosciences, Inc. (CBIO) are buried across hundreds of SEC pages. Every 10-K dissects protease-based pipeline data, and each 8-K may reveal trial results that can move the share price overnight. For investors tracking a pre-revenue biotech, missing one sentence on convertible equity or FDA feedback can be costly. That’s why finding Catalyst Biosciences insider trading Form 4 transactions or sifting through a Catalyst Biosciences quarterly earnings report 10-Q filing often feels like decoding lab notes.
Stock Titan solves this research bottleneck. Our AI reads every submission the moment it hits EDGAR, delivering Catalyst Biosciences SEC filings explained simply. Need the latest Catalyst Biosciences Form 4 insider transactions real-time? You’ll receive instant alerts. Curious about cash burn trends? Our dashboard links the numbers inside a Catalyst Biosciences earnings report filing analysis to previous quarters. We even flag dilution risks hidden in shelf registrations and translate risk-factor language, so understanding Catalyst Biosciences SEC documents with AI becomes effortless.
Whether you’re checking a Catalyst Biosciences annual report 10-K simplified for R&D expenses, comparing a Catalyst Biosciences proxy statement executive compensation to peers, or reviewing Catalyst Biosciences 8-K material events explained after a trial update, every disclosure is organized in one place. Track Catalyst Biosciences executive stock transactions Form 4, monitor option grants, and see real-time updates without opening a single PDF. Save hours, stay ahead of market-moving biotech news, and make decisions with clarity.
Crescent Biopharma, Inc. filed a Form S-8 to register ordinary shares for equity compensation plans following its merger and redomiciliation. The filing covers 2,345,962 shares under the 2025 Stock Incentive Plan, 195,497 shares under the 2025 Employee Stock Purchase Plan, 3,684,330 shares under the 2024 Equity Incentive Plan (for assumed options from the merger), and 1,250,000 shares under the 2025 Employment Inducement Incentive Award Plan.
The company completed a business combination with Crescent Biopharma Operating Company on June 13, 2025 and, on June 16, 2025, changed its jurisdiction of incorporation to the Cayman Islands. The filing also details director and officer indemnification provisions consistent with Cayman law and lists the relevant plan documents and consents as exhibits.
Crescent Biopharma (CBIO) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $24.6 million for the quarter and $61.5 million year‑to‑date, driven primarily by research and development of preclinical oncology programs.
Cash and cash equivalents were $133.3 million as of September 30, 2025, and management expects this balance to fund operations for at least twelve months from the financial statement issuance date. Operating cash outflow was $44.8 million for the nine months. R&D expense was $20.3 million in Q3 ($43.1 million YTD); G&A was $5.5 million in Q3 ($18.1 million YTD).
During 2025 the company completed a reverse recapitalization with GlycoMimetics, raised capital via a pre‑closing financing, converted $37.5 million of convertible notes into equity, and redomesticated to the Cayman Islands. Shareholders’ equity improved to $116.6 million from a deficit at year‑end 2024. Ordinary shares outstanding were 13,892,516 as of November 3, 2025.
Crescent Biopharma (CBIO)Exhibit 99.1.
The Company states this information is being furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth. The report is signed by CEO Joshua Brumm.
Crescent Biopharma, Inc. received a Schedule 13G disclosing that Tang Capital entities and Kevin Tang together hold 700,000 ordinary shares, representing 5.04% of the outstanding class based on 13,892,562 shares. The filing breaks ownership across Tang Capital Management, LLC, Tang Capital Partners, LP (393,681 shares, 2.84%), Tang Capital Partners International, LP (306,319 shares, 2.20%), and Kevin Tang, with shared voting and dispositive power over the full position. The statement affirms the position was not acquired to change or influence control.
FAQ
What is the current stock price of Crescent Biopharma (cbio)?
What is the market cap of Crescent Biopharma (cbio)?
